Skip to content
Abierto
Menu

Justification

Radiopharmaceutical PLUVICTO

36C24826Q0189

Department of Veterans Affairs, 248-Network Contract Office 8. Pharmaceutical Preparation Manufacturing.

View on SAM.govMarkdown

Awarded

Novartis Pharmaceuticals Corporation

$4,732,607.88 on the award notice, February 24, 2026, contract 36F79720D0180

Description

As published on SAM.gov.

See attached Justification PDF.

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Novartis Pharmaceuticals Corporation
UEI
NG61ZA8TADW3
CAGE
04520
Vendor location
East Hanover, NJ
Contract
36C26126F0007 under 36F79720D0180, delivery order
Obligated
$3,987,496.80
Actions
1 between October 1, 2025 and October 1, 2025
Competition
Full and Open Competition, 1 offer received
Described as
Pluvicto Drug
Match
solicitation number 36C26126F0007 was reused as the contract number; same awarding office 36C261 (high confidence)
Record
USAspending award page
Recipient
Novartis Pharmaceuticals Corporation
UEI
NG61ZA8TADW3
CAGE
04520
Vendor location
East Hanover, NJ
Contract
36C26126F0008 under 36F79720D0180, delivery order
Obligated
$679,948.64, potential $3,399,743
Actions
1 between October 1, 2025 and October 1, 2025
Competition
Full and Open Competition, 1 offer received
Described as
Lutathera Cancer Therapy
Match
solicitation number 36C26126F0008 was reused as the contract number; same awarding office 36C261 (high confidence)
Record
USAspending award page
Recipient
Novartis Pharmaceuticals Corporation
UEI
NG61ZA8TADW3
CAGE
04520
Vendor location
East Hanover, NJ
Contract
36F79720D0180
Obligated
$0.00, potential $20,809,675,896
Actions
68 between January 3, 2024 and July 27, 2026
Competition
Full and Open Competition, 999 offers received
Set-aside reported
No Set Aside Used.
Described as
Pharmaceuticals
Match
award number 36F79720D0180 equals the contract number; same sub-agency 3600 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. October 1, 2025

    Justification, originally special notice

    Justification and Approval Notice

    SAM.gov, notice 28aa306305524208a5d729f6edad42f4

  2. October 2, 2025

    Justification

    PLUVICTO - LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML

    SAM.gov, notice 989e5b8b353642b8a071507670bdb678

  3. October 10, 2025

    Special notice

    PLUVICTO | LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML VA Phoenix Healthcare System

    Due October 31, 2025 at 1:00 PM EDT. SAM.gov, notice ec5c22a742b640c89c1f8ff374a126d6

  4. January 8, 2026

    Award notice, originally justification

    Pluvicto | VA Phoenix Healthcare System

    Awarded to Novartis Pharmaceuticals Corporation East Hanover for $4,984,371. SAM.gov, notice 6dcee1676c804ae398aa4f70e62ba55f

  5. January 8, 2026

    Justification

    LSJ | Pluvicto | VA Phoenix Healthcare System

    SAM.gov, notice 857a6976b24a4b728ccc10c41a0e31fd

  6. March 3, 2026

    Justification

    Awarded to Novartis Pharmaceuticals Corporation East Hanover 07936 for $4,732,608. SAM.gov, notice f35d3000335f4f348dbe4993452441a1

Points of contact

Also open from this buyer